Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

NCT ID: NCT04181762

Last Updated: 2025-05-16

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 275 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-07-07
• Study Completion Date: 2023-09-13

Brief Summary

This was a pivotal, randomized, double-blind, placebo-controlled trial evaluating at Week 52 the efficacy and safety of secukinumab versus placebo in patients with active lupus nephritis (ISN/RPS Class III or IV, with or without co-existing class V features) also receiving background standard of care therapy (SoC).

Detailed Description

The study consisted of the following parts:

• Screening (up to 42 days/6 weeks)
• Run-in period (optional): For subjects who received Mycophenolic acid (MPA) as SoC induction therapy as per investigator's decision and who were not already on MPA at Screening, MPA dosing was initiated during a run-in period before Randomization (for up to 4 weeks prior to the first dose of secukinumab)
• Treatment Period: Duration of 104 weeks of treatment with secukinumab/placebo in addition to SoC treatment (with last dose given at Week 100)
• Secukinumab dosing was started with initial dosing of 300 mg s.c. injections at Baseline, Weeks 1, 2, 3, and 4, followed by dosing every 4 weeks
• Follow-up period: Duration of 8 weeks (last visit performed 12 weeks after last dose of study medication) for all except for subjects entering extension study CAIN457Q12301E1 (NCT05232864).

A total of 275 subjects were enrolled and were randomized to secukinumab 300 mg (n = 137) or placebo (n = 138) until study termination. Recruitment in this study was stopped on 26-May-2023. The CAIN457Q12301 study was terminated early by Novartis due to futile results from interim analysis 1 (IA1). There was no safety related reasons for early termination or concerns for the subjects in the study. The decision was made to terminate both the core and the related extension study in view of treatment futility of the core study.

Conditions

Lupus Nephritis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

secukinumab

A blinded, weekly, subcutaneous (s.c.) secukinumab 300 mg loading regimen was administered for the first 4 weeks followed by a monthly maintenance dose in all randomized subjects thereafter.

Group Type: EXPERIMENTAL

secukinumab

Intervention Type: DRUG

STUDY DRUG

placebo

A blinded, weekly, subcutaneous (s.c.) matching placebo loading regimen was administered for the first 4 weeks followed by a monthly maintenance dose in all randomized subjects thereafter.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo

Interventions

secukinumab

STUDY DRUG

Intervention Type: DRUG

Placebo

Placebo

Intervention Type: DRUG

Other Intervention Names

AIN457

Eligibility Criteria

Inclusion Criteria

1. Adult male and female subjects aged 18 - 75 years old at the time of Baseline.

2. Confirmed diagnosis of:

• SLE with documented history of at least 4 of the 11 criteria for SLE as defined by the American College of Rheumatology (ACR) (Tan et al 1982) revised by (Hochberg 1997). [NOTE: The 4 criteria did not have to be present at the time of Screening], OR
• LN as the sole clinical criterion in the presence of ANA or anti-dsDNA antibodies.

3. Active lupus nephritis, as defined by meeting the 4 following criteria:

• Biopsy within 6 months prior to Screening visit indicating active glomerulonephritis WHO or ISN/RPS Class III or IV LN [excluding III (C), IV-S (C) and IV-G (C)]; patients are permitted to have co-existing Class V. If no biopsy was performed within 6 months of screening, a biopsy was to be performed during the Screening period
• UPCR ≥ 1 mg/mg at Screening.
• eGFR > 30 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).
• Active urinary sediment (presence of cellular casts (RBC or WBC casts)) or hematuria (> 5 RBC per high power field or above the laboratory reference range).

4. Subjects must have currently been on MPA, or willing to initiate SoC induction therapy for LN according to the institutional practices using MPA or low-dose CYC in addition to corticosteroids. For guidance, see published guidelines such as by (Bertsias et al 2012, Hahn et al 2012).

5. Subjects must had been treated with anti-malarials (e.g. hydroxychloroquine), unless contra-indicated, and the dose had been stable for at least 10 days prior to Randomization.

6. Able to provide signed informed consent.

Exclusion Criteria

1. Severe renal impairment as defined by i.) Stage 4 CKD, or ii.) presence of oliguria (defined as a documented urine volume < 400 mL/24 h), or iii.) ESRD required dialysis or transplantation.

2. Known intolerance/hypersensitivity to MPA, or oral corticosteroids, or any component of the study drug(s).

3. Subjects received any other biologic immunomodulatory therapy within 6 months prior to Screening, excluding belimumab where 3 months were acceptable.

4. Previous exposure to secukinumab (AIN457) or any other biologic drug targeting IL-17 or the IL-17 receptor.

5. Subjects received any investigational drug within 1 month or five times the half-life of enrollment, whichever was longer.

6. Receipt of more than 3000 mg i.v. pulse methylprednisolone (cumulative dose) within the 12 weeks prior to Baseline.

7. Treatment with a systemic calcineurin inhibitor (e.g. cyclosporine, tacrolimus) within 12 weeks prior to Baseline

8. CYC use (i.v. or oral) within the month prior to Baseline.

9. Subjects requiring dialysis within the previous 12 months before Screening.

10. History of renal transplant.

11. Any severe progressive or uncontrolled concurrent medical condition, including recent severe thromboembolic events, that, in the opinion of the principal investigator, renders the subject unsuitable for the trial.

12. Active ongoing inflammatory diseases that might confound the evaluation of the benefit of secukinumab therapy, including inflammatory bowel disease.

13. Presence of investigator-identified significant medical problems which at the investigator's discretion would prevent the subject from participating in the study, included but not limited to the following: myocarditis, pericarditis, poorly controlled seizure disorder, acute confusional state, depression, severe manifestations of neuropsychiatric SLE (NPSLE).

14. Chest X-ray, computerized tomography (CT) scan, or MRI with evidence of ongoing infectious or malignant process, obtained within 3 months preceding the Screening visit and evaluated by a qualified physician.

15. History of chronic, recurrent systemic infections, active tuberculosis infection, or active systemic infections during the last two weeks (exception: common cold) prior to Randomization.

16. Known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C at Screening or Randomization.

17. History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system treated or untreated within the past 5 years, regardless of whether there was evidence of local recurrence or metastases (except for skin Bowen's disease or basal cell carcinoma or actinic keratoses that had been treated with no evidence of recurrence in the past 12 weeks, carcinoma in situ of the cervix or non-invasive malignant colon polyps that had been removed).

18. Any of the following abnormal laboratory values on Screening evaluations as reported by Central Laboratory:

• Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or amylase > 2.5xULN
• Hemoglobin < 8g/dL
• Neutrophils < 1.0 x 109/L
• Platelet count < 50 x 109/L

21. Pregnant or lactating women. 22. Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they were using highly effective methods of contraception during the entire study or longer if required by locally approved prescribing information (e.g., in European Union (EU) 20 weeks). Of note: the highly effective methods of contraception were mandated due to SoC medications used as per protocol (MPA and CYC).

In case local regulations deviated from the contraception methods listed above, local regulations applied and were described in the informed consent form (ICF).

If stricter female or male contraception requirements were specified in the country-specific label for induction and maintenance standard of care medications, they had to be followed.

Note: Women were considered post-menopausal and not of childbearing potential if they had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks prior to enrollment. In the case of oophorectomy alone, only when the reproductive status of the woman had been confirmed by follow-up hormone level assessment was she considered not of childbearing potential.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

Locations

University Of Alabama

Birmingham, Alabama, United States

Kaiser Permanente Fontana

Fontana, California, United States

University of California LA

Los Angeles, California, United States

Arthritis and Rheum Dise Spec

Aventura, Florida, United States

Integral Rheumatology and Immunology Specialists IRIS

Plantation, Florida, United States

Piedmont Heart Institute

Atlanta, Georgia, United States

Beth Israel Deaconess Hospital

Boston, Massachusetts, United States

Ahmed Arif Medical Research Center

Grand Blanc, Michigan, United States

Novartis Investigative Site

Caba, Buenos Aires, Argentina

Novartis Investigative Site

Ciudad Autonoma de Bs As, Buenos Aires, Argentina

Novartis Investigative Site

Córdoba, , Argentina

Novartis Investigative Site

Westmead, New South Wales, Australia

Novartis Investigative Site

Fortaleza, Ceará, Brazil

Novartis Investigative Site

Porto Alegre, Rio Grande do Sul, Brazil

Novartis Investigative Site

Joinville, Santa Catarina, Brazil

Novartis Investigative Site

Santo André, São Paulo, Brazil

Novartis Investigative Site

São Paulo, São Paulo, Brazil

Novartis Investigative Site

São Paulo, São Paulo, Brazil

Novartis Investigative Site

São José do Rio Preto, , Brazil

Novartis Investigative Site

Toronto, Ontario, Canada

Novartis Investigative Site

Valdivia, Los Ríos Region, Chile

Novartis Investigative Site

Santiago, RM, Chile

Novartis Investigative Site

Concepción, , Chile

Novartis Investigative Site

Santiago, , Chile

Novartis Investigative Site

Nanning, Guangxi, China

Novartis Investigative Site

Shijiazhuang, Hebei, China

Novartis Investigative Site

Changsha, Hunan, China

Novartis Investigative Site

Nanchang, Jiangxi, China

Novartis Investigative Site

Binzhou, Shandong, China

Novartis Investigative Site

Chengdu, Sichuan, China

Novartis Investigative Site

Beijing, , China

Novartis Investigative Site

Beijing, , China

Novartis Investigative Site

Chongqing, , China

Novartis Investigative Site

Guangzhou, , China

Novartis Investigative Site

Shanghai, , China

Novartis Investigative Site

Shanghai, , China

Novartis Investigative Site

Wuhan, , China

Novartis Investigative Site

Medellín, Antioquia, Colombia

Novartis Investigative Site

Barranquilla, , Colombia

Novartis Investigative Site

Cali, , Colombia

Novartis Investigative Site

Cundinamarca, , Colombia

Novartis Investigative Site

Zagreb, , Croatia

Novartis Investigative Site

Prague, , Czechia

Novartis Investigative Site

Prague, , Czechia

Novartis Investigative Site

Prague, , Czechia

Novartis Investigative Site

Odense C, , Denmark

Novartis Investigative Site

Marseille, , France

Novartis Investigative Site

Mainz, , Germany

Novartis Investigative Site

Athens, , Greece

Novartis Investigative Site

Thessaloniki, , Greece

Novartis Investigative Site

Guatemala City, , Guatemala

Novartis Investigative Site

Guatemala City, , Guatemala

Novartis Investigative Site

Quetzaltenango, , Guatemala

Novartis Investigative Site

New Delhi, National Capital Territory of Delhi, India

Novartis Investigative Site

New Delhi, National Capital Territory of Delhi, India

Novartis Investigative Site

Padua, PD, Italy

Novartis Investigative Site

Toyoake, Aichi-ken, Japan

Novartis Investigative Site

Kitakyushu, Fukuoka, Japan

Novartis Investigative Site

Sendai, Miyagi, Japan

Novartis Investigative Site

Kurashiki, Okayama-ken, Japan

Novartis Investigative Site

Chūō, Yamanashi, Japan

Novartis Investigative Site

Mexicali, Baja California Norte, Mexico

Novartis Investigative Site

Mexico City, Mexico CP, Mexico

Novartis Investigative Site

Mérida, Yucatán, Mexico

Novartis Investigative Site

México, , Mexico

Novartis Investigative Site

Oslo, , Norway

Novartis Investigative Site

Santiago de Surco, Lima region, Peru

Novartis Investigative Site

Lipa City, Batangas, Philippines

Novartis Investigative Site

Iloilo City, , Philippines

Novartis Investigative Site

Manila, , Philippines

Novartis Investigative Site

Quezon, , Philippines

Novartis Investigative Site

Coimbra, , Portugal

Novartis Investigative Site

Guimarães, , Portugal

Novartis Investigative Site

Lisbon, , Portugal

Novartis Investigative Site

Porto, , Portugal

Novartis Investigative Site

Oradea, Jud Bihor, Romania

Novartis Investigative Site

Râmnicu Vâlcea, Vâlcea County, Romania

Novartis Investigative Site

Bucharest, , Romania

Novartis Investigative Site

Bucharest, , Romania

Novartis Investigative Site

Bucharest, , Romania

Novartis Investigative Site

Kazan', , Russia

Novartis Investigative Site

Kemerovo, , Russia

Novartis Investigative Site

Rostov-on-Don, , Russia

Novartis Investigative Site

Saint Petersburg, , Russia

Novartis Investigative Site

Yaroslavl, , Russia

Novartis Investigative Site

Piešťany, , Slovakia

Novartis Investigative Site

Seoul, Seocho Gu, South Korea

Novartis Investigative Site

Seoul, , South Korea

Novartis Investigative Site

Barcelona, Catalonia, Spain

Novartis Investigative Site

Santiago de Compostela, Galicia, Spain

Novartis Investigative Site

Vigo, Pontevedra, Spain

Novartis Investigative Site

Stockholm, , Sweden

Novartis Investigative Site

Sankt Gallen, , Switzerland

Novartis Investigative Site

Kaohsiung City, , Taiwan

Novartis Investigative Site

Taichung, , Taiwan

Novartis Investigative Site

Taichung, , Taiwan

Novartis Investigative Site

Taoyuan District, , Taiwan

Novartis Investigative Site

Bangkok, , Thailand

Novartis Investigative Site

Bangkok, , Thailand

Novartis Investigative Site

Bakırkoy Istanbul, , Turkey (Türkiye)

Novartis Investigative Site

Istanbul, , Turkey (Türkiye)

Novartis Investigative Site

Istanbul, , Turkey (Türkiye)

Novartis Investigative Site

Ho Chi Minh City, VNM, Vietnam

Novartis Investigative Site

Hanoi, , Vietnam

Novartis Investigative Site

Ho Chi Minh City, , Vietnam

Countries

United States; Argentina; Australia; Brazil; Canada; Chile; China; Colombia; Croatia; Czechia; Denmark; France; Germany; Greece; Guatemala; India; Italy; Japan; Mexico; Norway; Peru; Philippines; Portugal; Romania; Russia; Slovakia; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Turkey (Türkiye); Vietnam

References

Zhao MH, Cons Molina F, Aroca G, Tektonidou MG, Mathur A, Tangadpalli R, Sun R, Martin R, Pellet P, Ngoc Phuong Huynh T. Secukinumab in active lupus nephritis: Results from phase III, randomised, placebo-controlled study (SELUNE) and open-label extension study. Rheumatology (Oxford). 2025 Oct 15:keaf536. doi: 10.1093/rheumatology/keaf536. Online ahead of print.

Reference Type: DERIVED

PMID: 41092316 (View on PubMed)

Avasare R, Drexler Y, Caster DJ, Mitrofanova A, Jefferson JA. Management of Lupus Nephritis: New Treatments and Updated Guidelines. Kidney360. 2023 Oct 1;4(10):1503-1511. doi: 10.34067/KID.0000000000000230.

Reference Type: DERIVED

PMID: 37528520 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=2291

A Plain Language Trial Summary is available on www.novctrd.com

Other Identifiers

2019-003211-57

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

PACTR202211748997845

Identifier Type: OTHER

Identifier Source: secondary_id

CAIN457Q12301

Identifier Type: -

Identifier Source: org_study_id